Stay updated with breaking news from Klinge Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
02.08.2023 - – Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA autoinjector launched in late May, and YUSIMRY launched in July –– Planned merger with Surface Oncology ...
Coherus to Acquire Surface Oncology - Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple... | June 16, 2023
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing... | June 16, 2023
–Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiplenext-generationimmunotherapies in clinical development funded bygrowing revenues –
– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation... | May 8, 2023